您的购物车当前为空
PD-1/PD-L1-IN-23为一种高效的口服活性PD-1/PD-L1抑制剂,是L7酯类的前药形式。L7为苯并[c][1,2,5]恶二唑衍生物,作为PD-L1抑制剂在生物学上进行评估。PD-1/PD-L1-IN-23在同基因和PD-L1人源化小鼠的肿瘤模型中展现出显著的抗肿瘤效果。

PD-1/PD-L1-IN-23为一种高效的口服活性PD-1/PD-L1抑制剂,是L7酯类的前药形式。L7为苯并[c][1,2,5]恶二唑衍生物,作为PD-L1抑制剂在生物学上进行评估。PD-1/PD-L1-IN-23在同基因和PD-L1人源化小鼠的肿瘤模型中展现出显著的抗肿瘤效果。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 25 mg | ¥ 17,200 | 10-14周 | |
| 50 mg | ¥ 22,800 | 10-14周 | |
| 100 mg | ¥ 29,500 | 10-14周 |
PD-1/PD-L1-IN-23 相关产品
| 产品描述 | PD-1/PD-L1-IN-23 is a potent, orally active ester prodrug of L7, a benzooxadiazole derivative, and functions as an inhibitor of PD-1/PD-L1. It has been biologically evaluated for its inhibitory effects on PD-L1, demonstrating significant antitumor effects in both syngeneic tumor models and PD-L1 humanized mice. |
| 分子量 | 703.41 |
| 分子式 | C32H30BrCl2N3O6 |
| CAS No. | 2597056-04-5 |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
评论内容